Jaakko J. Koskenniemi

Jaakko J. Koskenniemi

Auto-generated profile, based on publicly available information

Jaakko J. Koskenniemi

Department of Pediatrics, Turku University Hospital , Turku

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2018 in Endocrine Reviews
Verified
Journal Article
Closed access
PDF file
JMJuho-Antti Mäkelä
Juho-Antti Mäkelä
JKJaakko J Koskenniemi
Jaakko J Koskenniemi
HVHelena E Virtanen
Helena E Virtanen
JTJorma Toppari
Jorma Toppari
Production of sperm and androgens is the main function of the testis. This depends on normal development of both testicular somatic cells and germ cells. Genetic program initiated from the Y chromosome gene SRY (sex-determining region Y) directs somatic cell specification to Sertoli cells that orchestrate further development. They first guide fetal germ cell differentiation towards spermatogenic destiny, and then take care of the full service to spermatogenic cells during spermatogenesis. The number of Sertoli cells sets the limits of sperm production. Leydig cells secrete androgens that determine masculine development. Testis development does not depend on germ cells, i.e. testicular somatic cells also develop in the absence of germ cells, and the testis can produce testosterone normally to induce full masculinization in these men. In contrast, spermatogenic cell development is totally dependent on somatic cells. Here we review germ cell differentiation from primordial germ cells to spermatogonia and development of the supporting somatic cells. Testicular descent to scrota is necessary for normal spermatogenesis, and cryptorchidism is the most common male birth defect. This is a mild form of disorder of sex differentiation (DSD). Multiple genetic reasons for more severe forms of DSD have been revealed during the last decades, and these are described along the description of molecular regulation of testis development.

1 June 2017 in Current Opinion in Endocrinology, Diabetes and Obesity
Verified
Journal Article
Closed access
PDF file
JKJaakko J. Koskenniemi
Jaakko J. Koskenniemi
HVHelena E. Virtanen
Helena E. Virtanen
JTJorma Toppari
Jorma Toppari
Purpose of review: To describe pubertal testicular growth in humans, changes in testicular cell populations that result in testicular growth, and the role of testosterone and gonadotrophins follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in testicular growth. When human data were not available, studies in nonhuman primates and/or rodents were used as surrogates.Recent findings: Testicular growth in puberty follows a sigmoidal growth curve, with a large variation in timing of testicular growth and adult testicular volume. Testicular growth early in puberty is due to increase in Sertoli cell number and length of seminiferous tubules, whereas the largest and fastest growth results from the increase in the diameter of the seminiferous tubules first due to spermatogonial proliferation and then due to the expansion of meiotic and haploid germ cells. FSH stimulates Sertoli cell and spermatogonial proliferation, whereas LH/testosterone is mandatory to complete spermatogenesis. However, FSH and LH/testosterone work in synergy and are both needed for normal spermatogenesis.Summary: Testicular growth during puberty is rapid, and mostly due to germ cell expansion and growth in seminiferous tubule diameter triggered by androgens. Pre-treatment with FSH before the induction of puberty may improve the treatment of hypogonadotropic hypogonadism, but remains to be proven.

13 December 2011 in International Journal of Andrology
Verified
Journal Article
Open access
PDF file
HVH. E. Virtanen
H. E. Virtanen
JKJ. J. Koskenniemi
J. J. Koskenniemi
ESE. Sundqvist
E. Sundqvist
KMKatharina M. Main
Katharina M. Main
HKHannu Kiviranta
Hannu Kiviranta
JTJ. Toppari
J. Toppari
Summary: In animal studies, exposure to dioxins has been associated with disrupted development of the male reproductive system, including testicular maldescent. Some polychlorinated biphenyls (PCBs) have also dioxin‐like effects. In addition, one previous case–control study has reported an association between congenital cryptorchidism and colostrum PCB levels. We performed a case–control study to evaluate whether congenital cryptorchidism in boys was associated with increased levels of dioxins or PCBs in placenta reflecting foetal exposure. In addition, associations between placenta levels of these chemicals and reproductive hormone levels in boys at 3 months were studied. Placentas were collected in a Danish–Finnish joint prospective cohort study on cryptorchidism (1997–2001). The boys were examined for cryptorchidism at birth and at 3 months. Altogether, 280 placentas [112 Finnish (56 cases, 56 controls) and 168 Danish (39 cases, 129 controls)] were analysed for 17 toxic polychlorinated dibenzo‐p‐dioxins and dibenzofurans (PCDD/Fs) and 37 PCBs (including 12 dioxin‐like PCBs). Infant serum samples taken at 3 months were analysed for reproductive hormones. No significant differences between cases and controls were observed in either country in dioxin WHO‐TEq levels (median 9.78 vs. 8.47 pg/g fat, respectively, in Finland, and 11.75 vs. 10.88 pg/g fat in Denmark) or PCB WHO‐TEq levels (median 2.12 vs. 2.15 pg/g fat in Finland, 2.34 vs. 2.10 pg/g fat in Denmark) or total‐TEq levels (median 11.66 vs. 10.58 pg/g fat in Finland, 13.94 vs. 13.00 pg/g fat in Denmark). Placenta WHO‐TEq levels of dioxins were not associated with infant reproductive hormone levels at 3 months. In Finland, PCB WHO‐TEq levels in placenta associated positively with infant LH levels. WHO‐TEq levels of dioxins and PCBs and total‐TEq levels were higher in Danish than Finnish samples. In conclusion, no association between placenta levels of dioxins or PCBs and congenital cryptorchidism was found. Significant country differences in chemical levels were observed.

1 June 2016 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
SSSergey Sadov
Sergey Sadov
JKJaakko J. Koskenniemi
Jaakko J. Koskenniemi
HVHelena E. Virtanen
Helena E. Virtanen
APAntti Perheentupa
Antti Perheentupa
JPJørgen H. Petersen
Jørgen H. Petersen
JTJorma Toppari
Jorma Toppari
Article published by the Endocrine Society Article published by the Endocrine Society

23 July 2019 in Frontiers in Endocrinology
Verified
Journal Article
Open access
TKTanja Kuiri-Hänninen
Tanja Kuiri-Hänninen
JKJaakko Koskenniemi
Jaakko Koskenniemi
LDLeo Dunkel
Leo Dunkel
JTJorma Toppari
Jorma Toppari
USUlla Sankilampi
Ulla Sankilampi
Cryptorchidism, or undescended testis, is a well-known risk factor for testicular cancer and impaired semen quality in adulthood, conditions which have their origins in early fetal and postnatal life. In human pregnancy, the interplay of testicular and placental hormones as well as local regulatory factors and control by the hypothalamic-pituitary (HP) axis, lead to testicular descent by term. The normal masculine development may be disrupted by environmental factors or genetic defects and result in undescended testes. Minipuberty refers to the postnatal re-activation of the HP-testicular (T) axis after birth. During the first weeks of life, gonadotropin levels increase, followed by activation and proliferation of testicular Leydig, Sertoli and germ cells. Consequent rise in testosterone levels results in penile growth during the first months of life. Testicular size increases and testicular descent continues until three to five months of age. Insufficient HPT axis activation (e.g., hypogonadotropic hypogonadism) is often associated with undescended testis and therefore minipuberty is considered an important phase in the normal male reproductive development. Minipuberty provides a unique window of opportunity for the early evaluation of HPT axis function during early infancy. For cryptorchid boys, hormonal evaluation during minipuberty may give a hint of the underlying etiology and aid in the evaluation of the later risk of HPT axis dysfunction and impaired fertility. The aim of this review is to summarize the current knowledge of the role of minipuberty in testicular development and descent.

24 September 2015 in Environmental Health
Verified
Journal Article
Open access
PDF file
JKJaakko J. Koskenniemi
Jaakko J. Koskenniemi
HVHelena E. Virtanen
Helena E. Virtanen
HKHannu Kiviranta
Hannu Kiviranta
IDIda N. Damgaard
Ida N. Damgaard
JMJaakko Matomäki
Jaakko Matomäki
JTJorma Toppari
Jorma Toppari
Congenital cryptorchidism, i.e. failure of the testicular descent to the bottom of the scrotum, is a common birth defect. The evidence from epidemiological, wildlife, and animal studies suggests that exposure to mixtures of endocrine disrupting chemicals during fetal development may play a role in its pathogenesis. We aimed to assess the association between cryptorchidism and prenatal exposure to polychlorinated biphenyls (PCBs), polychlorinated dibenzo-p-dioxins and furans (PCDD/Fs), and polybrominated diphenyl ethers (PBDEs). We conducted a case–control study consisting of 44 cryptorchid cases, and 38 controls operated for inguinal hernia, umbilical hernia, or hydrocele at the Turku University Hospital or Rigshospitalet, Copenhagen in 2002–2006. During the operation a subcutaneous adipose tissue biopsy was taken. Samples were analysed for 37 PCBs, 17 PCDD/Fs and 14 PBDEs by gas chromatography-high-resolution mass spectrometry. Chemical concentrations were adjusted for postnatal variation introduced by differences in duration of breastfeeding, age at the operation, and country of origin with a multiple linear regression. Association between adjusted and unadjusted chemical concentrations and the risk of cryptorchidism were analysed with logistic regression to get an estimate for odds ratio (OR) of cryptorchidism per multiplication of chemical concentrations with ca. 2.71 (Napier’s constant). Total-TEq i.e. the WHO-recommended 2,3,7,8-TCDD equivalent quantity of 17 dioxins and 12 dioxin-like PCBs and sum of PCDD/Fs were positively associated with cryptorchidism [OR 3.21 (95 % CI 1.29–9.09), OR 3.69 (95 % CI 1.45–10.9), respectively], when adjusting for country of origin, the duration the child was breastfed, and age at operation. The association between the sum of PCBs and cryptorchidism was close to significant [OR 1.92 (95 % CI 0.98–4.01)], whereas the association between the sum of PBDEs and cryptorchidism was not [OR 0.86 (95 % CI 0.47–1.54)]. There were no associations between unadjusted chemical concentrations and the risk of cryptorchidism. Prenatal exposure to PCDD/Fs and PCDD/F-like PCBs may be associated with increased risk for cryptorchidism. Our finding does not exclude the possibility of an association between the exposure to PBDEs and cryptorchidism.